Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium
about
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and managementA randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.Immune checkpoint pathways: perspectives on myeloid malignancies.Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure.An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A.Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party.Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy.Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.
P2860
Q26796240-627BE030-7840-4AB5-9E3D-1FB67803D629Q38372745-2962999C-EC36-4456-9107-D2BB8E1F274CQ38392081-17E9F1BA-ABB1-419E-B619-9F290458CDBFQ38411523-CE9D9B1B-6FCC-4BA3-BCD5-8C9A86286488Q38570399-726081B7-CC56-4CBD-BC19-53C3A6F43EEDQ38750608-EFA6E45E-6127-4878-BD9D-8C8344CA8294Q39205101-3CA17412-0BBD-40AE-B733-843BFCB3F9A9Q40261354-0DD4BF04-AADC-46C9-948E-B915AA4FDAFCQ43480924-BA5C5B28-2C57-490A-8A05-D5473243FC54Q45624632-803F7A66-3084-4492-BCBD-1111B4BEA509Q47548041-0240458B-515E-496A-83D9-F41D8034B19DQ52901403-684AB943-F815-4F9A-93AA-CF2F56A128ACQ54602748-4B089174-1A31-4C29-B871-D2F2C207B0B3
P2860
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Outcome of patients with low-r ...... S Clinical Research Consortium
@ast
Outcome of patients with low-r ...... S Clinical Research Consortium
@en
type
label
Outcome of patients with low-r ...... S Clinical Research Consortium
@ast
Outcome of patients with low-r ...... S Clinical Research Consortium
@en
prefLabel
Outcome of patients with low-r ...... S Clinical Research Consortium
@ast
Outcome of patients with low-r ...... S Clinical Research Consortium
@en
P2093
P2860
P50
P356
P1433
P1476
Outcome of patients with low-r ...... S Clinical Research Consortium
@en
P2093
Alan F List
Amy Dezern
Asmita Mishra
David P Steensma
Elias J Jabbour
Eric Padron
Gail J Roboz
Jeffrey Lancet
Mikkael A Sekeres
Najla H Al Ali
P2860
P304
P356
10.1002/CNCR.29145
P407
P577
2014-11-19T00:00:00Z